A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions

Science Translational Medicine

Volumn 9, Issue 372, 2017, Pages

  Damelin, Marc ^a   Bankovich, Alexander ^b   Bernstein, Jeffrey ^b   Lucas, Justin ^a   Chen, Liang ^a   Williams, Samuel ^b   Park, Albert ^b   Aguilar, Jorge ^b   Ernstoff, Elana ^a   Charati, Manoj ^a   Dushin, Russell ^a   Aujay, Monette ^b   Lee, Christina ^b   Ramoth, Hanna ^b   Milton, Milly ^b   Hampl, Johannes ^b   Lazetic, Sasha ^b   Pulito, Virginia ^a   Rosfjord, Edward ^a   Sun, Yongliang ^a   King, Lindsay ^a   Barletta, Frank ^a   Betts, Alison ^a   Guffroy, Magali ^a   Falahatpisheh, Hadi ^a   O'Donnell, Christopher J ^a   Stull, Robert ^b   Pysz, Marybeth ^b   Escarpe, Paul ^b   Liu, David ^b   Foord, Orit ^b   Gerber, Hans Peter ^a   Sapra, Puja ^a   Dylla, Scott J ^b   more..

^a PFIZER INC   (United States)

^b AbbVie Stemcentrx LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; AURISTATIN; CISPLATIN; DOCETAXEL; MONOCLONAL ANTIBODY H6M24 VC0101 CONJUGATE; PACLITAXEL; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 7; SAPORIN; UNCLASSIFIED DRUG; AMINOBENZOIC ACID DERIVATIVE; ANTIBODY; ANTIBODY CONJUGATE; CELL ADHESION MOLECULE; OLIGOPEPTIDE; PTK7 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BONE MARROW SUPPRESSION; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; EC50; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; INTERNALIZATION; LONG TERM SURVIVAL; MACACA FASCICULARIS; MITOSIS INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NON SMALL CELL LUNG CANCER; NONHUMAN; OVARY CANCER; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PTK7 GENE; TRIPLE NEGATIVE BREAST CANCER; TUMOR CELL; TUMOR INITIATING CELL; TUMOR REGRESSION; ANIMAL; CANCER STEM CELL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG SCREENING; DRUG THERAPY; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; LUNG TUMOR; MICROTUBULE; NONOBESE DIABETIC MOUSE; OVARY TUMOR; PROCEDURES; SCID MOUSE; TUMOR CELL LINE; TUMOR RECURRENCE;

AMINOBENZOATES; ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; LUNG NEOPLASMS; MACACA FASCICULARIS; MICE; MICE, INBRED NOD; MICE, SCID; MICROTUBULES; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC STEM CELLS; OLIGOPEPTIDES; OVARIAN NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85010700290     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aag2611     Document Type: Article

References (61)

1. T. Reya, S. J. Morrison, M. F. Clarke, I. L. Weissman, Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
2. J. E. Visvader, G. J. Lindeman, Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768 (2008).
3. B.-B. S. Zhou, H. Zhang, M. Damelin, K. G. Geles, J. C. Grindley, P. B. Dirks, Tumourinitiating cells: Challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 8, 806-823 (2009).
4. J. Lee, S. Kotliarova, Y. Kotliarov, A. Li, Q. Su, N. M. Donin, S. Pastorino, B. W. Purow, N. Christopher, W. Zhang, J. K. Park, H. A. Fine, Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391-403 (2006).
5. A. Li, J. Walling, Y. Kotliarov, A. Center, M. E. Steed, S. J. Ahn, M. Rosenblum, T. Mikkelsen, J. C. Zenklusen, H. A. Fine, Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol. Cancer Res. 6, 21-30 (2008).
6. E. Rosfjord, J. Lucas, G. Li, H.-P. Gerber, Advances in patient-derived tumor xenografts: From target identification to predicting clinical response rates in oncology. Biochem. Pharmacol. 91, 135-143 (2014).
7. S. A. Williams, W. C. Anderson, M. T. Santaguida, S. J. Dylla, Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. Lab. Invest. 93, 970-982 (2013).
8. M. Damelin, A. Bankovich, A. Park, J. Aguilar, W. Anderson, M. Santaguida, M. Aujay, S. Fong, K. Khandke, V. Pulito, E. Ernstoff, P. Escarpe, J. Bernstein, M. Pysz, W. Zhong, E. Upeslacis, J. Lucas, J. Lucas, T. Nichols, K. Loving, O. Foord, J. Hampl, R. Stull, F. Barletta, H. Falahatpisheh, P. Sapra, H.-P. Gerber, S. J. Dylla, Anti-EFNA4 calicheamicin conjugates effectively target triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regressions. Clin. Cancer Res. 21, 4165-4173 (2015).
9. E. L. Sievers, P. D. Senter, Antibody-drug conjugates in cancer therapy. Annu. Rev. Med. 64, 15-29 (2013).
10. A. Mullard, Maturing antibody-drug conjugate pipeline hits Nat. Rev. Drug Discov. 12, 329-332 (2013).
11. M. R. Junttila, W. Mao, X. Wang, B.-E. Wang, T. Pham, J. Flygare, S.-F. Yu, S. Yee, D. Goldenberg, C. Fields, J. Eastham-Anderson, M. Singh, R. Vij, J.-A. Hongo, R. Firestein, M. Schutten, K. Flagella, P. Polakis, A. G. Polson, Targeting LGR5+ cells with an antibody-drug conjugate for the treatment of colon cancer. Sci. Transl. Med. 7, 314ra186 (2015).
12. P. Sapra, M. Damelin, J. Dijoseph, K. Marquette, K. G. Geles, J. Golas, M. Dougher, B. Narayanan, A. Giannakou, K. Khandke, R. Dushin, E. Ernstoff, J. Lucas, M. Leal, G. Hu, C. J. O'Donnell, L. Tchistiakova, R. T. Abraham, H.-P. Gerber, Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol. Cancer Ther. 12, 38-47 (2013).
13. H.-P. Gerber, P. Sapra, F. Loganzo, C. May, Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect? Biochem. Pharmacol. 102, 1-6 (2016).
14. P. Müller, M. Kreuzaler, T. Khan, D. S. Thommen, K. Martin, K. Glatz, S. Savic, N. Harbeck, U. Nitz, O. Gluz, M. von Bergwelt-Baildon, H. Kreipe, S. Reddy, M. Christgen, A. Zippelius, Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. Sci. Transl. Med. 7, 315ra188 (2015).
15. J. Boudeau, D. Miranda-Saavedra, G. J. Barton, D. R. Alessi, Emerging roles of pseudokinases. Trends Cell Biol. 16, 443-452 (2006).
16. N. Bin-Nun, H. Lichtig, A. Malyarova, M. Levy, S. Elias, D. Frank, PTK7 modulates Wnt signaling activity via LRP6. Development 141, 410-421 (2014).
17. M. Hayes, M. Naito, A. Daulat, S. Angers, B. Ciruna, Ptk7 promotes non-canonical Wnt/PCP-mediated morphogenesis and inhibits Wnt/b-catenin-dependent cell fate decisions during vertebrate development. Development 140, 1807-1818 (2013).
18. X. Lu, A. G. Borchers, C. Jolicoeur, H. Rayburn, J. C. Baker, M. Tessier-Lavigne, PTK7/CCK-4 is a novel regulator of planar cell polarity in vertebrates. Nature 430, 93-98 (2004).
19. S. Martinez, P. Scerbo, M. Giordano, A. M. Daulat, A.-C. Lhoumeau, V. Thomé, L. Kodjabachian, J.-P. Borg, The PTK7 and ROR2 protein receptors interact in the vertebrate WNT/Planar Cell Polarity (PCP) pathway. J. Biol. Chem. 290, 30562-30572 (2015).
20. H. Peradziryi, N. S. Tolwinski, A. Borchers, The many roles of PTK7: A versatile regulator of cell-cell communication. Arch. Biochem. Biophys. 524, 71-76 (2012).
21. R. Chen, P. Khatri, P. K. Mazur, M. Polin, Y. Zheng, D. Vaka, C. D. Hoang, J. Shrager, Y. Xu, S. Vicent, A. J. Butte, E. A. Sweet-Cordero, A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma. Cancer Res. 74, 2892-2902 (2014).
22. L. Meng, K. Sefah, M. B. O'Donoghue, G. Zhu, D. Shangguan, A. Noorali, Y. Chen, L. Zhou, W. Tan, Silencing of PTK7 in colon cancer cells: Caspase-10-dependent apoptosis via mitochondrial pathway. PLOS ONE 5, e14018 (2010).
23. W.-S. Shin, J. Kwon, H. W. Lee, M. C. Kang, H.-W. Na, S.-T. Lee, J. H. Park, Oncogenic role of protein tyrosine kinase 7 in esophageal squamous cell carcinoma. Cancer Sci. 104, 1120-1126 (2013).
24. A.-C. Lhoumeau, S. Martinez, J.-M. Boher, G. Monges, R. Castellano, A. Goubard, M. Doremus, F. Poizat, B. Lelong, C. de Chaisemartin, F. Bardin, P. Viens, J.-L. Raoul, T. Prebet, M. Aurrand-Lions, J.-P. Borg, A. Gonçalves, Overexpression of the promigratory and prometastatic PTK7 receptor is associated with an adverse clinical outcome in colorectal cancer. PLOS ONE 10, e0123768 (2015).
25. S. Gärtner, A. Gunesch, T. Knyazeva, P. Wolf, B. Hogel, W. Eiermann, A. Ullrich, P. Knyazev, B. Ataseven, PTK 7 is a transforming gene and prognostic marker for breast cancer and nodal metastasis involvement. PLOS ONE 9, e84472 (2014).
26. T. Prebet, A.-C. Lhoumeau, C. Arnoulet, A. Aulas, S. Marchetto, S. Audebert, F. Puppo, C. Chabannon, D. Sainty, M.-J. Santoni, M. Sebbagh, V. Summerour, Y. Huon, W.-S. Shin, S.-T. Lee, B. Esterni, N. Vey, J.-P. Borg, The cell polarity PTK7 receptor acts as a modulator of the chemotherapeutic response in acute myeloid leukemia and impairs clinical outcome. Blood 116, 2315-2323 (2010).
27. A. W. Tolcher, E. Calvo, M. L. Maitland, B. Gibson, D. Xuan, T. Joh, A. Jackson-Fisher, M. Damelin, J. Barton, X. Xin, J. C. Sachdev, 28LBA A phase 1 study of PF-06647020, an antibody-drug conjugate targeting PTK7, in patients with advanced solid tumors, paper presented at the European Cancer Congress, Vienna, 2015.
28. Cancer Genome Atlas Network, Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
29. Cancer Genome Atlas Research Network, Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
30. Cancer Genome Atlas Research Network, Comprehensive genomic characterization of squamous cell lung cancers. Nature 489, 519-525 (2012).
31. P. J. Stephens, P. S. Tarpey, H. Davies, P. Van Loo, C. Greenman, D. C. Wedge, S. Nik-Zainal, S. Martin, I. Varela, G. R. Bignell, L. R. Yates, E. Papaemmanuil, D. Beare, A. Butler, A. Cheverton, J. Gamble, J. Hinton, M. Jia, A. Jayakumar, D. Jones, C. Latimer, K. W. Lau, S. McLaren, D. J. McBride, A. Menzies, L. Mudie, K. Raine, R. Rad, M. S. Chapman, J. Teague, D. Easton, A. Langerød; Oslo Breast Cancer Consortium (OSBREAC), M. T. M. Lee, C.-Y. Shen, B. T. K. Tee, B. W. Huimin, A. Broeks, A. C. Vargas, G. Turashvili, J. Martens, A. Fatima, P. Miron, S.-F. Chin, G. Thomas, S. Boyault, O. Mariani, S. R. Lakhani, M. van de Vijver, L. van 't Veer, J. Foekens, C. Desmedt, C. Sotiriou, A. Tutt, C. Caldas, J. S. Reis-Filho, S. A. J. R. Aparicio, A. V. Salomon, A.-L. Børresen-Dale, A. L. Richardson, P. J. Campbell, P. A. Futreal, M. R. Stratton, The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404 (2012).
32. A. Maderna, M. Doroski, C. Subramanyam, A. Porte, C. A. Leverett, B. C. Vetelino, Z. Chen, H. Risley, K. Parris, J. Pandit, A. H. Varghese, S. Shanker, C. Song, S. C. Sukuru, K. A. Farley, M. M. Wagenaar, M. J. Shapiro, S. Musto, M.-H. Lam, F. Loganzo, C. J. O'Donnell, Discovery of cytotoxic dolastatin 10 analogues with N-terminal modifications. J. Med. Chem. 57, 10527-10543 (2014).
33. N. Haddish-Berhane, D. K. Shah, D. Ma, M. Leal, H.-P. Gerber, P. Sapra, H. A. Barton, A. M. Betts, On translation of antibody drug conjugates efficacy from mouse experimental tumors to the clinic: A PK/PD approach. J. Pharmacokinet. Pharmacodyn. 40, 557-571 (2013).
34. W.-S. Shin, Y.-S. Maeng, J.-W. Jung, J.-K. Min, Y.-G. Kwon, S.-T. Lee, Soluble PTK7 inhibits tube formation, migration, and invasion of endothelial cells and angiogenesis. Biochem. Biophys. Res. Commun. 371, 793-798 (2008).
35. S. S. Chang, V. E. Reuter, W. D. Heston, N. H. Bander, L. S. Grauer, P. B. Gaudin, Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 3192-3198 (1999).
36. V. S. Golubkov, A. Y. Strongin, Insights into ectodomain shedding and processing of protein-tyrosine pseudokinase 7 (PTK7). J. Biol. Chem. 287, 42009-42018 (2012).
37. H. Saber, J. K. Leighton, An FDA oncology analysis of antibody-drug conjugates. Regul. Toxicol. Pharmacol. 71, 444-452 (2015).
38. M. Damelin, W. Zhong, J. Myers, P. Sapra, Evolving strategies for target selection for antibody-drug conjugates. Pharm. Res. 32, 3494-3507 (2015).
39. K. Mossie, B. Jallal, F. Alves, I. Sures, G. D. Plowman, A. Ullrich, Colon carcinoma kinase-4 defines a new subclass of the receptor tyrosine kinase family. Oncogene 11, 2179-2184 (1995).
40. S. A. Mani, W. Guo, M.-J. Liao, E. N. Eaton, A. Ayyanan, A. Y. Zhou, M. Brooks, F. Reinhard, C. C. Zhang, M. Shipitsin, L. L. Campbell, K. Polyak, C. Brisken, J. Yang, R. A. Weinberg, The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715 (2008).
41. A.-P. Morel, M. Lièvre, C. Thomas, G. Hinkal, S. Ansieau, A. Puisieux, Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLOS ONE 3, e2888 (2008).
42. S. Liu, Y. Cong, D. Wang, Y. Sun, L. Deng, Y. Liu, R. Martin-Trevino, L. Shang, S. P. McDermott, M. D. Landis, S. Hong, A. Adams, R. D'Angelo, C. Ginestier, E. Charafe-Jauffret, S. G. Clouthier, D. Birnbaum, S. T. Wong, M. Zhan, J. C. Chang, M. S. Wicha, Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports 2, 78-91 (2013).
43. A. Roesch, M. Fukunaga-Kalabis, E. C. Schmidt, S. E. Zabierowski, P. A. Brafford, A. Vultur, D. Basu, P. Gimotty, T. Vogt, M. Herlyn, A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141, 583-594 (2010).
44. D. A. Lawson, N. R. Bhakta, K. Kessenbrock, K. D. Prummel, Y. Yu, K. Takai, A. Zhou, H. Eyob, S. Balakrishnan, C.-Y. Wang, P. Yaswen, A. Goga, Z. Werb, Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells. Nature 526, 131-135 (2015).
45. T. Brabletz, To differentiate or not-Routes towards metastasis. Nat. Rev. Cancer 12, 425-436 (2012).
46. G. Kroemer, L. Senovilla, L. Galluzzi, F. André, L. Zitvogel, Natural and therapy-induced immunosurveillance in breast cancer. Nat. Med. 21, 1128-1138 (2015).
47. P. Muller, K. Martin, S. Theurich, J. Schreiner, S. Savic, G. Terszowski, D. Lardinois, V. A. Heinzelmann-Schwarz, M. Schlaak, H.-M. Kvasnicka, G. Spagnoli, S. Dirnhofer, D. E. Speiser, M. von Bergwelt-Baildon, A. Zippelius, Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol. Res. 2, 741-755 (2014).
48. S. Demoulin, M. Herfs, P. Delvenne, P. Hubert, Tumor microenvironment converts plasmacytoid dendritic cells into immunosuppressive/tolerogenic cells: Insight into the molecular mechanisms. J. Leukoc. Biol. 93, 343-352 (2013).
49. M. Swiecki, M. Colonna, The multifaceted biology of plasmacytoid dendritic cells. Nat. Rev. Immunol. 15, 471-485 (2015).
50. K. Hack, L. Reilly, C. Proby, C. Fleming, I. Leigh, J. Foerster, Wnt5a inhibits the CpG oligodeoxynucleotide-triggered activation of human plasmacytoid dendritic cells. Clin. Exp. Dermatol. 37, 557-561 (2012).
51. Y. Pak, Y. Zhang, I. Pastan, B. Lee, Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors. Cancer Res. 72, 3143-3152 (2012).
52. F. S. Hodi, D. Lawrence, C. Lezcano, X. Wu, J. Zhou, T. Sasada, W. Zeng, A. Giobbie-Hurder, M. B. Atkins, N. Ibrahim, P. Friedlander, K. T. Flaherty, G. F. Murphy, S. Rodig, E. F. Velazquez, M. C. Mihm Jr., S. Russell, P. J. DiPiro, J. T. Yap, N. Ramaiya, A. D. Van den Abbeele, M. Gargano, D. McDermott, Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res. 2, 632-642 (2014).
53. M. Al-Hajj, M. S. Wicha, A. Benito-Hernandez, S. J. Morrison, M. F. Clarke, Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 100, 3983-3988 (2003).
54. P. Dalerba, S. J. Dylla, I. K. Park, R. Liu, X. Wang, R. W. Cho, T. Hoey, A. Gurney, E. H. Huang, D. M. Simeone, A. A. Shelton, G. Parmiani, C. Castelli, M. F. Clarke, Phenotypic characterization of human colorectal cancer stem cells. Proc. Natl. Acad. Sci. U.S.A. 104, 10158-10163 (2007).
55. B. Györffy, P. Surowiak, J. Budczies, A. Lánczky, Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLOS ONE 8, e82241 (2013).
56. A. Mortazavi, B. A. Williams, K. McCue, L. Schaeffer, B. Wold, Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5, 621-628 (2008).
57. M. E. Ritchie, B. Phipson, D. Wu, Y. Hu, C. W. Law, W. Shi, G. K. Smyth, limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
58. S. W. Hui, D. A. Stenger, Electrofusion of cells: Hybridoma production by electrofusion and polyethylene glycol. Methods Enzymol. 220, 212-227 (1993).
59. O. Foord, S. J. Dylla, R. A. Stull, A. Bankovich, A. L. L. Lazetic, J. Bernstein, U.S. Patent 9, 409, 995 (2016).
60. M. Doroski, A. Maderna, C. J. O'Donnell, C. Subramanyam, B. C. Vetelino, R. Dushin, P. Strop, E. I. Graziani, U.S. Patent 8, 828, 401 (2014).
61. M. N. Nakatsu, C. C. W. Hughes, An optimized three-dimensional in vitro model for the analysis of angiogenesis. Methods Enzymol. 443, 65-82 (2008).